In an effort to expand its cancer treatment offerings, Bristol Myers Squibb plans to acquire RayzeBio, a radiopharmaceutical therapeutics company. The deal is worth $4.1 billion, the companies announced Dec. 26.
Read the full post on Becker's Hospital Review - Healthcare News
